PPD Earns Industry Recognition for Clinical Research Excellence
Honored as Team of the Year at PharmaTimes’ annual competition
WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced that PharmaTimes magazine named a group of PPD clinical research associates (CRAs) the 2014 Clinical Research Team of the Year.
“The PharmaTimes competition is demanding, and I credit our success to this talented team and PPD’s dedication to providing world-class training for its clinical researchers.”
The PPD CRAs, Cian Brennan, Amanda Fleming, Dominique Ross and Louise Smith, were selected as the top performing team from among finalists in a rigorous three-stage competition. For the finals, teams faced a series of drug development challenges and presented solutions to a panel of industry judges. Winners were determined by their responses to follow-up questions that assessed their knowledge, innovation, creativity and ability to collaborate. The award was presented during a ceremony held Jan. 30 in London.
“PPD’s focus on setting the industry standard for clinical research performance provides clients confidence in our CRAs’ knowledge and skills to conduct on-site monitoring with the highest quality,” said Roger Newbery, PPD’s vice president of clinical development for Europe, the Middle East and Africa. “The PharmaTimes competition is demanding, and I credit our success to this talented team and PPD’s dedication to providing world-class training for its clinical researchers.”
Before PPD CRAs enter the field, they are prepared to monitor clinical trials with PPD’s industry-leading clinical foundation program utilizing PPD® 3D, an award-winning, virtual learning environment. For clinical research, PPD applies the latest technology and processes – such as PPD’s innovative real-time data and analysis solution PreclarusTM and adaptive and intelligent monitoring – to ensure compliance with protocols and industry standards, while delivering high-quality service to help clients advance drug development.
The Clinical Research Team of the Year recognition is the latest of several recent PharmaTimes honors earned by PPD CRAs, including the 2013 U.S. Clinical Researcher of the Year, the 2013 Clinical Research Associate of the Year and 2012 Clinical Team of the Year award.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s PharmaTimes award and CRA performance, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.